The current board is composed of nine members and is led by founder and chair of the board of directors, Mariam S. Darsot.
The appointments come as Nexus works to expand its offerings to include new products as well as Nexus Pharma Services.
Lee is the Founder and Managing Member of Sagent Group and brings over twenty years of experience investing in and advising companies in the life sciences and technology, media, and telecommunications industries.
Prior to the founding of Sagent Group, he served as the founder and portfolio manager of Oaktree's USD 6bn Strategic Credit strategy as well as serving as CEO and CIO of the organization's three business development companies.
Lee also brings experience from his work in TMT investment banking at UBS in Los Angeles, fixed income at Lehman Brothers, management consulting at Katzenbach Partners (Booz & Co.) and economic research at the Urban Institute.
He holds a B.A. degree in economics from Swarthmore College and a master's degree from Harvard University.
Warmuth was most recently an Operating Partner at EW Healthcare Partners from 2018 to 2022.
Prior to EW Healthcare Partners, Warmuth was at Abbott Laboratories, where he led the Established Pharmaceuticals division which soon became one of the top ten largest generics companies across the globe and covered several therapeutic areas including gastroenterology, women's health, cardiovascular, and metabolic disorders.
His work at Abbott reflects a strong track record of success in driving operational excellence and growth through mergers and acquisitions. He holds a B.A. degree in Business Administration from the University of Wisconsin-Whitewater and a master's degree from Northwestern University.
Upsher-Smith launches Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%
Torrent Pharma starts shipping generic Keveyis (dichlorphenamide), 50mg tablets in US
Upsher-Smith Laboratories introduces Fluphenazine Hydrochloride Tablets
American Regent launches sulphite-free Epinephrine Injection
Teva and Natco Launch Additional Strengths for the Generic Version of Revlimid in the US
Accord Healthcare adds Teriflunomide to oral medications range